Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x100
Organisation › Details

Proteomedix AG

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnostics. The company has identified novel biomarker signatures with utility in prostate cancer diagnostics, prognostics and therapy management. Their lead product Proclarix® is a blood based prostate cancer test panel and risk score and will be introduced to the market early 2020. Proteomedix is located in the Biotechnopark of Schlieren, Switzerland. *

 

Period Start 2010-01-01 established (s-off)
  Predecessor ETH Zürich (ETHZ)
Products Industry Proclarix® blood-based prostate cancer test panel and risk score
  Industry 2 personalised medicine / precision medicine
Persons Person Lubenow, Helge (Proteomedix 202001– CEO before Consultant before 1997–2015 at Qiagen)
  Person 2 Brühlmann, Christian (Proteomedix 202001 COO/CFO)
     
Region Region Schlieren ZH
  Country Switzerland
  Street 21 Wagistr.
Bio-Technopark
  City 8952 Schlieren ZH
  Tel +41-44-733-4090
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Proteomedix AG. (1/10/20). "Press Release: Proteomedix Appoints Helge Lubenow as New CEO". Zürich-Schlieren.
     
   
Record changed: 2021-12-02

Advertisement

Picture Berlin Partner Voices from Berlin-Brandenburg Georg Duda 650x200px

More documents for Proteomedix AG


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x300




» top